Recommendations for Genetic Testing to Reduce the Incidence of Anthracycline-induced Cardiotoxicity

Aminkeng, Folefac; Ross, Colin J D; Rassekh, Shahrad R; Hwang, Soomi; Rieder, Michael J; Bhavsar, Amit P; Smith, Anne; Sanatani, Shubhayan; Gelmon, Karen A; Bernstein, Daniel; Hayden, Michael R; Carleton, Bruce C; Amstutz, Ursula (2016). Recommendations for Genetic Testing to Reduce the Incidence of Anthracycline-induced Cardiotoxicity. British journal of clinical pharmacology, 82(3), pp. 683-695. Wiley-Blackwell 10.1111/bcp.13008

[img] Text
bcp13008.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (594kB) | Request a copy

AIM Anthracycline-induced cardiotoxicity (ACT) occurs in 57% of treated patients and remains an important limitation of anthracycline-based chemotherapy. In various genetic association studies, potential genetic risk markers for ACT have been identified. Therefore, we developed evidence-based clinical practice recommendations for pharmacogenomic testing to further individualize therapy based on ACT risk. METHODS We followed a standard guideline development process; including a systematic literature search, evidence synthesis and critical appraisal, and the development of clinical practice recommendations with an international expert group. RESULTS RARG rs2229774, SLC28A3 rs7853758 and UGT1A6 rs17863783 variants currently have the strongest and the most consistent evidence for association with ACT. Genetic variants in ABCC1, ABCC2, ABCC5, ABCB1, ABCB4, CBR3, RAC2, NCF4, CYBA, GSTP1, CAT, SULT2B1, POR, HAS3, SLC22A7, SCL22A17, HFE and NOS3 have also been associated with ACT, but require additional validation. We recommend pharmacogenomic testing for the RARG rs2229774 (S427L), SLC28A3 rs7853758 (L461L) and UGT1A6*4 rs17863783 (V209V) variants in childhood cancer patients with an indication for doxorubicin or daunorubicin therapy (Level B - moderate). Based on an overall risk stratification, taking into account genetic and clinical risk factors, we recommend a number of management options including increased frequency of echocardiogram monitoring, follow-up, as well as therapeutic options within the current standard of clinical practice. CONCLUSIONS Existing evidence demonstrates that genetic factors have the potential to improve the discrimination between individuals at higher and lower risk of ACT. Genetic testing may therefore support both patient care decisions and evidence development for an improved prevention of ACT.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Institute of Clinical Chemistry

UniBE Contributor:

Amstutz, Ursula

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0306-5251

Publisher:

Wiley-Blackwell

Language:

English

Submitter:

Ursula Amstutz

Date Deposited:

13 Jul 2016 11:42

Last Modified:

22 Sep 2017 10:06

Publisher DOI:

10.1111/bcp.13008

PubMed ID:

27197003

Uncontrolled Keywords:

anthracycline; cancer; cardiotoxicity; guidelines; heart-failure; pharmacogenomics

BORIS DOI:

10.7892/boris.82722

URI:

https://boris.unibe.ch/id/eprint/82722

Actions (login required)

Edit item Edit item
Provide Feedback